[go: up one dir, main page]

BR0009083A - Derivado de amida, processo para a preparação de um derivado de amida, composição farmacêutica, uso de um derivado de amida, método de tratamento de doenças ou de condições médicas mediadas por citocinas - Google Patents

Derivado de amida, processo para a preparação de um derivado de amida, composição farmacêutica, uso de um derivado de amida, método de tratamento de doenças ou de condições médicas mediadas por citocinas

Info

Publication number
BR0009083A
BR0009083A BR0009083-2A BR0009083A BR0009083A BR 0009083 A BR0009083 A BR 0009083A BR 0009083 A BR0009083 A BR 0009083A BR 0009083 A BR0009083 A BR 0009083A
Authority
BR
Brazil
Prior art keywords
amide derivative
medical conditions
aryl
amino
pharmaceutical composition
Prior art date
Application number
BR0009083-2A
Other languages
English (en)
Other versions
BR0009083B1 (pt
Inventor
Dearg Sutherland Brown
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9906279.6A external-priority patent/GB9906279D0/en
Priority claimed from GBGB9926667.8A external-priority patent/GB9926667D0/en
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of BR0009083A publication Critical patent/BR0009083A/pt
Publication of BR0009083B1 publication Critical patent/BR0009083B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C07D239/91—Oxygen atoms with aryl or aralkyl radicals attached in position 2 or 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

"DERIVADO DE AMIDA, PROCESSO PARA A PREPARAçãO DE UM DERIVADO DE AMIDA, COMPOSIçãO FARMACêUTICA, USO DE UM DERIVADO DE AMIDA, MéTODO DE TRATAMENTO DE DOENçAS OU DE CONDIçõES MéDICAS MEDIADAS POR CITOCINAS". A invenção refere-se aos derivados de amida de fórmula (Ia) na qual X é -NHCO- ou -CONH-; m é 0-3; R^ 1^ um grupo tal como hidróxi, halogênio, trifluoro-metila, ciano, mercapto, nitro, amino, carboxila e carbamoila; n é 0-2; R^ 2^ é um grupo tal como hidróxi, halogênio, trifluorometila, ciano, mercapto, nitro, amino e carboxila; W é hidrogênio, halogênio, (1-6C)alquila ou (1-6C)alcoxila; q é 0-4; e Q é um grupo tal como arila, ariloxila, aril-(1-6C)alcoxila, aril-amino e N-(1-6C)alquil-aril-amino; ou seus sais farmaceuticamente aceitáveis ou seus ésteres cliváveis in vivo; aos processos para sua preparação, às composições contendo-os e ao seu uso no tratamento de doenças ou de condições médicas mediadas por citocinas.
BRPI0009083-2A 1999-03-17 2000-03-13 derivado de amida compreendendo um núcleo de quinazolinona, processo para a preparação de um derivado de amida, composição farmacêutica, e, uso de um derivado de amida. BR0009083B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9906279.6A GB9906279D0 (en) 1999-03-17 1999-03-17 Amide derivatives
GBGB9926667.8A GB9926667D0 (en) 1999-11-11 1999-11-11 Amide derivatives
PCT/GB2000/000912 WO2000055153A1 (en) 1999-03-17 2000-03-13 Amide derivatives

Publications (2)

Publication Number Publication Date
BR0009083A true BR0009083A (pt) 2002-01-02
BR0009083B1 BR0009083B1 (pt) 2011-11-01

Family

ID=26315301

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0009083-2A BR0009083B1 (pt) 1999-03-17 2000-03-13 derivado de amida compreendendo um núcleo de quinazolinona, processo para a preparação de um derivado de amida, composição farmacêutica, e, uso de um derivado de amida.

Country Status (27)

Country Link
US (3) US7008945B1 (pt)
EP (1) EP1163237B1 (pt)
JP (1) JP4619545B2 (pt)
KR (1) KR100757282B1 (pt)
CN (1) CN1178932C (pt)
AR (1) AR028988A1 (pt)
AT (1) ATE266023T1 (pt)
AU (1) AU761453B2 (pt)
BR (1) BR0009083B1 (pt)
CA (1) CA2368097C (pt)
CZ (1) CZ300293B6 (pt)
DE (1) DE60010448T2 (pt)
DK (1) DK1163237T3 (pt)
ES (1) ES2219319T3 (pt)
HU (1) HUP0105114A3 (pt)
IL (2) IL145357A0 (pt)
MX (1) MXPA01009307A (pt)
MY (1) MY128501A (pt)
NO (1) NO323191B1 (pt)
NZ (1) NZ514195A (pt)
PL (1) PL200804B1 (pt)
PT (1) PT1163237E (pt)
RU (1) RU2260007C2 (pt)
SK (1) SK287238B6 (pt)
TR (1) TR200103336T2 (pt)
TW (1) TWI247745B (pt)
WO (1) WO2000055153A1 (pt)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9816837D0 (en) 1998-08-04 1998-09-30 Zeneca Ltd Amide derivatives
US7772432B2 (en) 1991-09-19 2010-08-10 Astrazeneca Ab Amidobenzamide derivatives which are useful as cytokine inhibitors
AU739066B2 (en) 1997-09-23 2001-10-04 Astrazeneca Ab Amide derivatives for the treatment of diseases mediated by cytokines
PT1077931E (pt) 1998-05-15 2005-03-31 Astrazeneca Ab Derivados de bezamida para o tratamento de doencas mediadas por citocinas
BR9910467A (pt) 1998-05-15 2001-01-09 Astrazeneca Ab Composto derivado de amida, processo para a preparação do mesmo, composição farmacêutica, e, uso de um composto derivado de amida
TR200100300T2 (tr) 1998-08-04 2001-07-23 Astrazeneca Ab Sitokinlerin üretiminde engelleyici olarak kullanışlı amid türevleri
JP2002525358A (ja) 1998-09-25 2002-08-13 アストラゼネカ アクチボラグ ベンズアミド誘導体及びサイトカイン阻害剤としてのその使用
DE60022328T2 (de) 1999-03-17 2006-06-01 Astrazeneca Ab Amid-derivate
TR200103336T2 (tr) 1999-03-17 2002-04-22 Astrazeneca Ab Amid türevleri.
GB9906566D0 (en) 1999-03-23 1999-05-19 Zeneca Ltd Chemical compounds
GB9924092D0 (en) 1999-10-13 1999-12-15 Zeneca Ltd Pyrimidine derivatives
DE10155075A1 (de) * 2001-11-09 2003-05-22 Merck Patent Gmbh Cyclische Sulfonamide
ES2278170T3 (es) 2002-07-09 2007-08-01 BOEHRINGER INGELHEIM PHARMA GMBH & CO.KG Composiciones farmaceuticas de anticolinergicos e inhibidores de la quinasa p38 en el tratamiento de enfermedades respiratorias.
ES2295816T3 (es) 2003-01-14 2008-04-16 Arena Pharmaceuticals, Inc. Derivados arilo y heteroarilo 1,2,3-trisustituidos como moduladores del metabolismo, y profilaxis y tratamiento de transtornos relacionados con los mismos, tales como la diabetes y la hiperglucemia.
GB0324790D0 (en) 2003-10-24 2003-11-26 Astrazeneca Ab Amide derivatives
RU2390520C2 (ru) * 2003-12-22 2010-05-27 Адзиномото Ко., Инк. Новые производные фенилаланина
BRPI0512075A (pt) * 2004-06-15 2008-02-06 Astrazeneca Ab composto, processo para a preparação do mesmo, composição farmacêutica, uso de um composto, e, métodos para a produção de um efeito inibidor de b-raf, e de um efeito anticáncer em um animal de sangue quente, e para o tratamento de uma doença
US20060035893A1 (en) 2004-08-07 2006-02-16 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for treatment of respiratory and gastrointestinal disorders
PE20060777A1 (es) 2004-12-24 2006-10-06 Boehringer Ingelheim Int Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas
CN102516170A (zh) * 2004-12-24 2012-06-27 阿斯利康(瑞典)有限公司 酰胺衍生物
GB0504019D0 (en) 2005-02-26 2005-04-06 Astrazeneca Ab Amide derivatives
MX2007016463A (es) * 2005-06-22 2008-03-04 Plexxikon Inc Derivados de pirrolo [2,3-b] piridina como inhibidores de proteina cinasa.
GB0516570D0 (en) * 2005-08-12 2005-09-21 Astrazeneca Ab Amide derivatives
JP2009541310A (ja) * 2006-06-19 2009-11-26 アストラゼネカ・アクチエボラーグ イソキノリン誘導体およびサイトカイン仲介疾患の阻害剤としてのそれらの使用
US7834023B2 (en) * 2006-09-20 2010-11-16 Portola Pharmaceuticals, Inc. Substituted dihydroquinazolines as platelet ADP receptor inhibitors
WO2008063888A2 (en) 2006-11-22 2008-05-29 Plexxikon, Inc. Compounds modulating c-fms and/or c-kit activity and uses therefor
CL2008000973A1 (es) 2007-04-05 2009-01-02 Astrazeneca Ab Compuestos derivados de 1-oxo-isoquinolina; procedimiento de preparación; composición farmacéutica; y su uso en el tratamiento de enfermedades pulmonares obstructvas crónicas (epoc) y asma.
EP1992344A1 (en) 2007-05-18 2008-11-19 Institut Curie P38 alpha as a therapeutic target in pathologies linked to FGFR3 mutation
AU2008276063B2 (en) 2007-07-17 2013-11-28 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
US7868001B2 (en) * 2007-11-02 2011-01-11 Hutchison Medipharma Enterprises Limited Cytokine inhibitors
AR073711A1 (es) 2008-10-01 2010-11-24 Astrazeneca Ab Derivados de isoquinolina
BRPI1008709B8 (pt) 2009-04-03 2021-05-25 Hoffmann La Roche dispersão sólida, formulação, composição e comprimido compreendendo {3-[5-(4-cloro-fenil)-1h-pirrol[2,3-b]piridina-3-carbonil]-2,4-diflúor-fenil}-amida do ácido propano-1-sulfônico
US20110112127A1 (en) 2009-11-06 2011-05-12 Plexxikon, Inc. Compounds and methods for kinase modulation, and indications therefor
EP2619198A1 (en) 2010-09-22 2013-07-31 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
MY162950A (en) 2011-02-07 2017-07-31 Plexxikon Inc Compounds and methods for kinase modulation, and indications therefor
AR085279A1 (es) 2011-02-21 2013-09-18 Plexxikon Inc Formas solidas de {3-[5-(4-cloro-fenil)-1h-pirrolo[2,3-b]piridina-3-carbonil]-2,4-difluor-fenil}-amida del acido propano-1-sulfonico
US9181226B2 (en) * 2011-07-18 2015-11-10 Merck Patent Gmbh Benzamides
DE102012101680A1 (de) * 2012-02-29 2013-08-29 Aicuris Gmbh & Co. Kg Pharmazeutische Zubereitung enthaltend ein antiviral wirksames Dihydrochinazolinderivat
US9150570B2 (en) 2012-05-31 2015-10-06 Plexxikon Inc. Synthesis of heterocyclic compounds
GB201317609D0 (en) 2013-10-04 2013-11-20 Cancer Rec Tech Ltd Inhibitor compounds
JO3512B1 (ar) 2014-03-26 2020-07-05 Astex Therapeutics Ltd مشتقات كينوكسالين مفيدة كمعدلات لإنزيم fgfr كيناز
PL3242666T3 (pl) 2015-01-06 2025-02-17 Arena Pharmaceuticals, Inc. Związek do zastosowania w leczeniu dolegliwości związanych z receptorem s1p1
GB201505658D0 (en) 2015-04-01 2015-05-13 Cancer Rec Tech Ltd Inhibitor compounds
JP6838744B2 (ja) 2015-06-22 2021-03-03 アリーナ ファーマシューティカルズ， インコーポレイテッド Ｓ１Ｐ１レセプター関連障害における使用のための（Ｒ）−２−（７−（４−シクロペンチル−３−（トリフルオロメチル）ベンジルオキシ）−１，２，３，４−テトラヒドロシクロペンタ［ｂ］インドール−３−イル）酢酸（化合物１）の結晶性Ｌ−アルギニン塩
WO2017003723A1 (en) 2015-07-01 2017-01-05 Crinetics Pharmaceuticals, Inc. Somatostatin modulators and uses thereof
ES2904513T3 (es) 2015-09-23 2022-04-05 Janssen Pharmaceutica Nv 1,4-Benzodiazepinas biheteroarilo sustituidas y usos de las mismas para el tratamiento del cáncer
EP3353177B1 (en) 2015-09-23 2020-06-03 Janssen Pharmaceutica NV Tricyclic heterocycles for the treatment of cancer
US20190060286A1 (en) 2016-02-29 2019-02-28 University Of Florida Research Foundation, Incorpo Chemotherapeutic Methods
GB201617103D0 (en) 2016-10-07 2016-11-23 Cancer Research Technology Limited Compound
AU2018220521A1 (en) 2017-02-16 2019-09-05 Arena Pharmaceuticals, Inc. Compounds and methods for treatment of primary biliary cholangitis
EP3658560A4 (en) 2017-07-25 2021-01-06 Crinetics Pharmaceuticals, Inc. SOMATOSTAT IN MODULATORS AND USES THEREOF
AR112840A1 (es) 2017-09-29 2019-12-18 Bayer Ag 3- fenilquinazolin-4(3h)-onas sustituidas y sus usos
WO2019063708A1 (en) 2017-09-29 2019-04-04 Bayer Aktiengesellschaft SUBSTITUTED 3-PHENYLQUINAZOLIN-4 (3H) -ONES AND USES THEREOF
KR102859841B1 (ko) 2018-06-06 2025-09-12 아레나 파마슈티칼스, 인크. S1p1 수용체와 관련된 병태의 치료 방법
KR102658602B1 (ko) 2018-10-31 2024-04-19 길리애드 사이언시즈, 인코포레이티드 Hpk1 억제 활성을 갖는 치환된 6-아자벤즈이미다졸 화합물
EP4371987B9 (en) 2018-10-31 2025-11-26 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds as hpk1 inhibitors
WO2020237025A1 (en) 2019-05-23 2020-11-26 Gilead Sciences, Inc. Substituted exo-methylene-oxindoles which are hpk1/map4k1 inhibitors
CN115551593A (zh) * 2020-04-08 2022-12-30 雷密克斯医疗公司 用于调节剪接的化合物和方法

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1903899A (en) 1933-04-18 Cabboxylic acid abylides oe the benzene sebies and process oe making
DE522788C (de) 1928-11-01 1931-04-15 I G Farbenindustrie Akt Ges Verfahren zur Darstellung von Carbonsaeurearyliden der Benzolreihe
US1909960A (en) 1929-08-06 1933-05-23 Du Pont Intermediate for azo dyes
NL272900A (pt) 1960-12-23
US3755332A (en) 1971-07-01 1973-08-28 Ciba Geigy Corp Substituted 4 indazolaminoquinolines
DE2812252A1 (de) 1978-03-21 1979-10-04 Bayer Ag 1,2,4-triazol-blockierte polyisocyanate als vernetzer fuer lackbindemittel
US4367328A (en) 1981-03-05 1983-01-04 The Dow Chemical Company Epoxy resins from hydroxy benzamides
US4524168A (en) 1981-11-18 1985-06-18 Ciba-Geigy Corporation Process for the mass coloration of polymers
US4749729A (en) 1984-06-21 1988-06-07 American Cyanamid Company Epoxy resin compositions curable above 160 F. and below 250 F.
JPS61204221A (ja) 1985-03-07 1986-09-10 Hitachi Chem Co Ltd 熱硬化性樹脂組成物
US5710158A (en) 1991-05-10 1998-01-20 Rhone-Poulenc Rorer Pharmaceuticals Inc. Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
ZA924666B (en) * 1991-06-27 1993-12-24 Takeda Chemical Industries Ltd Heterocyclic compounds, their production and use
WO1993004170A1 (en) 1991-08-23 1993-03-04 The United States Of America Represented By The Secretary, Department Of Health And Human Services Raf protein kinase therapeutics
GB9816837D0 (en) 1998-08-04 1998-09-30 Zeneca Ltd Amide derivatives
AU661533B2 (en) 1992-01-20 1995-07-27 Astrazeneca Ab Quinazoline derivatives
GB9314884D0 (en) 1993-07-19 1993-09-01 Zeneca Ltd Tricyclic derivatives
IL112249A (en) 1994-01-25 2001-11-25 Warner Lambert Co Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds
US5550132A (en) * 1994-06-22 1996-08-27 University Of North Carolina Hydroxyalkylammonium-pyrimidines or purines and nucleoside derivatives, useful as inhibitors of inflammatory cytokines
JPH11510511A (ja) 1995-08-10 1999-09-14 メルク エンド カンパニー インコーポレーテッド ２，５−置換アリールピロール、この化合物を含有する組成物及び使用方法
EP1304322A3 (en) 1995-08-22 2003-11-19 Japan Tobacco Inc. Carboxylic acid compound and use thereof
AR004010A1 (es) 1995-10-11 1998-09-30 Glaxo Group Ltd Compuestos heterociclicos
GB9604926D0 (en) 1996-03-08 1996-05-08 Sandoz Ltd Organic compounds
EP0888335A4 (en) 1996-03-13 2002-01-02 Smithkline Beecham Corp NEW PYRIMIDINE COMPOUNDS AND THEIR USE IN THE TREATMENT OF CYTOKININ MEDIATOR DISEASES
WO1998006715A1 (en) 1996-08-09 1998-02-19 Smithkline Beecham Corporation Novel piperazine containing compounds
GB9623833D0 (en) 1996-11-16 1997-01-08 Zeneca Ltd Chemical compound
WO1999001439A1 (en) 1997-07-03 1999-01-14 Du Pont Pharmaceuticals Company Aryl-and arylamino-substituted heterocycles as corticotropin releasing hormone antagonists
ZA986732B (en) 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitiors of tyrosine kinases
AU739066B2 (en) 1997-09-23 2001-10-04 Astrazeneca Ab Amide derivatives for the treatment of diseases mediated by cytokines
ATE232521T1 (de) 1998-03-27 2003-02-15 Janssen Pharmaceutica Nv Hiv hemmende pyrimidin derivate
BR9910467A (pt) 1998-05-15 2001-01-09 Astrazeneca Ab Composto derivado de amida, processo para a preparação do mesmo, composição farmacêutica, e, uso de um composto derivado de amida
PT1077931E (pt) 1998-05-15 2005-03-31 Astrazeneca Ab Derivados de bezamida para o tratamento de doencas mediadas por citocinas
TR200100300T2 (tr) * 1998-08-04 2001-07-23 Astrazeneca Ab Sitokinlerin üretiminde engelleyici olarak kullanışlı amid türevleri
CA2341707C (en) 1998-08-27 2010-02-16 Sumitomo Pharmaceuticals Co., Ltd. Pyrimidine derivatives
ES2274634T3 (es) 1998-08-29 2007-05-16 Astrazeneca Ab Compuestos de pirimidina.
ATE336484T1 (de) 1998-08-29 2006-09-15 Astrazeneca Ab Pyrimidine verbindungen
JP2002525358A (ja) 1998-09-25 2002-08-13 アストラゼネカ アクチボラグ ベンズアミド誘導体及びサイトカイン阻害剤としてのその使用
EP1117653B1 (en) 1998-10-01 2003-02-05 AstraZeneca AB Quinoline and quinazoline derivatives and their use as inhibitors of cytokine mediated diseases
DE60022328T2 (de) 1999-03-17 2006-06-01 Astrazeneca Ab Amid-derivate
TR200103336T2 (tr) * 1999-03-17 2002-04-22 Astrazeneca Ab Amid türevleri.
GB9906566D0 (en) 1999-03-23 1999-05-19 Zeneca Ltd Chemical compounds
GB9924092D0 (en) 1999-10-13 1999-12-15 Zeneca Ltd Pyrimidine derivatives
CN1575177A (zh) 2000-12-11 2005-02-02 图拉里克公司 Cxcr3拮抗剂
TW200306839A (en) 2002-02-06 2003-12-01 Novartis Ag Quinazolinone derivatives and their use as CB agonists
GB0324790D0 (en) 2003-10-24 2003-11-26 Astrazeneca Ab Amide derivatives

Also Published As

Publication number Publication date
WO2000055153A1 (en) 2000-09-21
DK1163237T3 (da) 2004-08-02
AU761453B2 (en) 2003-06-05
PL200804B1 (pl) 2009-02-27
AU3177800A (en) 2000-10-04
PL350451A1 (en) 2002-12-16
NO323191B1 (no) 2007-01-15
PT1163237E (pt) 2004-08-31
CZ300293B6 (cs) 2009-04-15
SK13112001A3 (sk) 2002-06-04
TWI247745B (en) 2006-01-21
US7332483B2 (en) 2008-02-19
US20050245551A1 (en) 2005-11-03
IL145357A0 (en) 2002-06-30
SK287238B6 (sk) 2010-04-07
TR200103336T2 (tr) 2002-04-22
ES2219319T3 (es) 2004-12-01
US20060281734A1 (en) 2006-12-14
IL145357A (en) 2007-07-24
EP1163237A1 (en) 2001-12-19
ATE266023T1 (de) 2004-05-15
RU2260007C2 (ru) 2005-09-10
US7442704B2 (en) 2008-10-28
NO20014492D0 (no) 2001-09-14
EP1163237B1 (en) 2004-05-06
NO20014492L (no) 2001-11-12
HUP0105114A3 (en) 2002-09-30
HUP0105114A2 (hu) 2002-07-29
CN1178932C (zh) 2004-12-08
KR20010113756A (ko) 2001-12-28
CZ20013319A3 (cs) 2001-12-12
NZ514195A (en) 2004-05-28
HK1041885A1 (en) 2002-07-26
JP4619545B2 (ja) 2011-01-26
MXPA01009307A (es) 2002-07-30
CA2368097A1 (en) 2000-09-21
US7008945B1 (en) 2006-03-07
JP2002539207A (ja) 2002-11-19
CA2368097C (en) 2010-01-19
BR0009083B1 (pt) 2011-11-01
DE60010448D1 (de) 2004-06-09
DE60010448T2 (de) 2005-04-07
AR028988A1 (es) 2003-06-04
KR100757282B1 (ko) 2007-09-11
MY128501A (en) 2007-02-28
CN1350530A (zh) 2002-05-22

Similar Documents

Publication Publication Date Title
BR0009083A (pt) Derivado de amida, processo para a preparação de um derivado de amida, composição farmacêutica, uso de um derivado de amida, método de tratamento de doenças ou de condições médicas mediadas por citocinas
BR0009041A (pt) Derivado de amida, processo para a preparação deum derivado de amida, composição farmacêutica,uso de um derivado de amida, e, método paratratar doenças ou quadros clìnicos mediados porcitocinas
BR9913947A (pt) Derivado de amida, processo para a preparação do mesmo ou um sal farmaceuticamente aceitável ou éster clivável in vivo deste, uso do mesmo, e, composição farmacêutica
BR0014596A (pt) Derivado de pirimidina, uso do mesmo, composição farmacêutica, e, método de tratar doenças ou condições médicas mediadas por citocinas
BR0308875A (pt) Composto ou um sal farmaceuticamente aceitável ou amida ou éster deste hidrolisável in vivo, processo para prepará-lo, composição farmacêutica, uso do composto da fórmula de um sal farmaceuticamente aceitável ou amida ou éster deste hidrolisável in vivo, e, métodos para produzir um efeito inibidor de hdac e para tratar o câncer em um animal de sangue quente, tal como o homem, em necessidade de tal tratamento
BR9910467A (pt) Composto derivado de amida, processo para a preparação do mesmo, composição farmacêutica, e, uso de um composto derivado de amida
BR9914162A (pt) Derivado de amida, processo para preparar um derivado de amida, ou um sal farmaceuticamente aceitável ou éster clivável in vivo do mesmo, composição farmacêutica e uso de um derivado de amida, ou um sal farmaceuticamente aceitável ou éster clivável in vivo do mesmo
BR0206435A (pt) Composto, composição farmacêutica, métodos de tratar a angiogênese em um paciente, de tratar distúrbios relacionados com kdr e proliferativos em um mamìfero, uso de um composto, e, processo para preparar compostos
IL127296A0 (en) Novel heterocyclic compounds process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases
BR9912729A (pt) Derivado de amida, processo para prepará-lo, e, uso do mesmo
WO2001064639A3 (en) Pde iv inhibiting amides, compositions and pharmaceutical use
BR0309553A (pt) Composto ou sal farmaceuticamente aceitável ou éster ou amida hidrolisável in vivo deste, processo para prepará-lo, composição farmacêutica, uso do composto, e, métodos para produzir um efeito inibidor de hdac em um animal de sangue quente, e para tratar câncer em um animal de sangue quente
AP2000001860A0 (en) Hypolipidemic benzothiazepine compounds.
BR0308816A (pt) Tiazolidina-4-carbonitrilas e análogos e seus usos como inibidores da dipeptil-peptidas
UA66852C2 (uk) Похідні та аналоги 3-арилпропіонової кислоти, спосіб їх отримання, фармацевтична композиція (варіанти) та спосіб профілактики та/або лікування асоційованих з резистентністю до інсуліну клінічних станів
PT1119567E (pt) Derivados de quinazolina
ATE381537T1 (de) Formanilid-derivative als beta2-adrenorezeptor- agonisten
DK0647219T3 (da) Derivater i vitamin D-serien modificeret i 20-positionen, fremgangsmåde til fremstilling af sådanne derivater, mellemprodukter itl brug ved fremgangsmåde, farmaceutiske præparater indeholdende derivaterne samt deres anvendelse ved fremstilling af lægemidler
HUT65351A (en) Process for preparing ethanolamine derivatives haring sympathominetic and anti-pollakiuria activity and pharmaceutical compositions containing them as active agent
BR0012157A (pt) Derivado de quinazolina, derivado de pirimidina, processo para a preparação de um derivado de quinazolina, composição farmacêutica, uso de um derivado de quinazolina, e, método para a prevenção ou tratamento de doenças ou condições médicas pela célula t um em animal de sangue quente em necessidade de tal tratamento
ATE201671T1 (de) Chinolon und acridinon derivate zur behandlung der harninkontinenz
NO20040589L (no) Arylsulfonylderivater med 5-HT6 reseptor affinitet.
ES2164109T3 (es) Derivados de n-(3-piperidinilcarbonil)-beta-alanina como antagonistas de paf.
BR0315958A (pt) Composto, composição farmacêutica, processo para a preparação de um composto, novos intermediários e uso do composto
HUP0401588A2 (hu) Rákellenes és proliferáció elleni hatású indeno[1,2-c]pirazol-4-on-származékok és ezeket tartalmazó gyógyszerkészítmények

Legal Events

Date Code Title Description
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 01/11/2011, OBSERVADAS AS CONDICOES LEGAIS.

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 14A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2259 DE 22-04-2014 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.